VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
FULC
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
FULCFulcrum Therapeutics, Inc.
$3.72$201M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksFULCFinancials

Fulcrum Therapeutics, Inc. (FULC) Income Statement

9Y historyFree accessUpdated daily

Revenue appeared in only one of the last ten quarters ($80.0M in 2024Q2), leaving operating losses of ~$19.9M in 2026Q2 driven by $12.4M of R&D, even as R&D was trimmed from $19.3M in 2024Q1 and roughly 70% of those savings were absorbed elsewhere in the cost base.

Income StatementBalance SheetCash FlowRatios

FULC Income Statement

Annual statement

FULC Income Statement

Fulcrum Therapeutics, Inc. (FULC) annual income statement — 9-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17
Sales/Revenue0080M2.81M6.34M19.16M8.82M000
Revenue Growth %--100%2752.05%-55.77%-66.91%117.19%----
Cost of Goods Sold554K1.39M63.39M71.8M76.78M69.7M59.04M2.05M1.34M715K
COGS % of Revenue--79.23%2559.75%1210.69%363.73%669.18%---
Gross Profit-554K-1.39M16.61M-69M-70.44M-50.54M-50.22M-2.05M-1.34M-715K
Gross Margin %--20.77%-2459.75%-1110.69%-263.73%-569.18%---
Gross Profit Growth %--108.37%124.08%2.05%-39.38%-0.64%-2346.13%-52.64%-88.11%-
Operating Expenses75.7M83.38M38.51M41.67M42.12M30.52M21.39M56.57M33.5M22.99M
OpEx % of Revenue--48.14%1485.49%664.16%159.24%242.46%---
Selling, General & Admin31.28M28.67M36.45M41.67M41.69M30.52M21.39M13.14M8.31M4.5M
SG&A % of Revenue--45.56%1485.49%657.43%159.24%242.46%---
Research & Development44.98M56.1M63.39M71.8M76.78M69.7M59.04M43.43M25.18M18.49M
R&D % of Revenue--79.23%2559.75%1210.69%363.73%669.18%---
Other Operating Expenses-554K-1.39M-61.32M-71.8M-76.36M-69.7M-59.04M0392K28K
Operating Income-76.25M-84.77M-21.9M-110.66M-112.56M-81.05M-71.61M-58.63M-33.5M-22.99M
Operating Margin %---27.37%-3945.24%-1774.85%-422.97%-811.64%---
Operating Income Growth %--287.13%80.21%1.69%-38.87%-13.19%-22.15%-75.01%-45.69%-
EBITDA-75.05M-83.38M-20.3M-108.49M-110.15M-78.54M-69.23M-56.57M-32.15M-22.28M
EBITDA Margin %---25.38%-3867.81%-1736.79%-409.85%-784.68%---
EBITDA Growth %6.3%-310.65%81.29%1.5%-40.24%-13.44%-22.38%-75.95%-44.33%-
D&A (Non-Cash Add-back)1.2M1.39M1.59M2.17M2.41M2.52M2.38M2.05M1.34M715K
EBIT-70.6M-74.88M-19.83M-97.33M-112.13M-80.85M-71.61M-82.68M-33.5M-22.99M
Net Interest Income00000207K792K1.51M00
Interest Income00000207K792K1.51M00
Interest Expense0000000000
Other Income/Expense-91K9.89M12.17M13.33M2.69M207K792K-24.05M910K29K
Pretax Income-76.34M-74.88M-9.72M-97.33M-109.87M-80.85M-70.82M-82.68M-32.59M-22.96M
Pretax Margin %---12.16%-3470.05%-1732.43%-421.89%-802.66%---
Income Tax000000000-1K
Effective Tax Rate %0%0%0%0%0%0%0%0%0%0%
Net Income-76.34M-74.88M-9.72M-97.33M-109.87M-80.85M-70.82M-82.68M-32.59M-22.96M
Net Margin %---12.16%-3470.05%-1732.43%-421.89%-802.66%---
Net Income Growth %-7.35%-669.97%90.01%11.41%-35.9%-14.16%14.34%-153.7%-41.91%-
Net Income (Continuing)-76.34M-74.88M-9.72M-97.33M-109.87M-80.85M-70.82M-82.68M-32.59M-22.96M
Discontinued Operations0000000000
Minority Interest0000000000
EPS (Diluted)-1.00-1.18-0.16-1.59-2.35-2.22-2.70-3.49-1.92-1.36
EPS Growth %11.86%-637.5%89.94%32.34%-5.86%17.78%22.64%-81.77%-41.18%-
EPS (Basic)--1.18-0.16-1.59-2.35-2.22-2.70-3.49-1.92-1.36
Diluted Shares Outstanding76.32M63.35M61.98M61.31M44.99M35.36M25.35M22.66M16.94M16.94M
Basic Shares Outstanding76.32M63.35M61.98M61.31M44.99M35.36M25.35M22.66M16.94M16.94M
Dividend Payout Ratio----------

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetMixed
Cash FlowBurning
Top Statement Risk

Absence of recurring revenue

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Revenue Concentrated in One Quarter

According to Fulcrum's reported income statements, revenue appeared in only one of the ten quarters reviewed, $80.0M in 2024Q2, with the remaining periods printing no top line and mechanically generating -100.0% growth comparisons that obscure underlying business direction.

The pattern suggests the top line is driven by episodic transactions rather than a repeatable commercial stream, which means the -100.0% growth prints in 2024Q3, 2024Q4 and 2025Q2 largely reflect the arithmetic of lapping one outsized period rather than genuine demand destruction. For an analyst, the durability question therefore rests on whether any emerging revenue line can be identified in subsequent disclosures; absent that, the company's trajectory is better characterized as pre-revenue than growing or contracting.

R&D Consumes the Cost Structure

Research and development spending of $12.4M in 2026Q2 remains the largest expense line, exceeding SG&A of $7.5M by roughly 65 percent and driving the operating loss despite negligible cost of goods sold, based on Fulcrum's quarterly income statement disclosures.

R&D has stepped down from $19.3M in 2024Q1 to $12.4M in 2026Q2, a decline of about 36 percent that may indicate program prioritization or trial-stage timing rather than structural discipline, while SG&A has been comparatively sticky in the $6.8M to $10.2M band. The implication is that overhead is not scaling down in tandem with research spend, so further loss reduction would appear to depend on the durability of the R&D cuts rather than on administrative efficiency.

2024Q2 Milestone Distorts the Baseline

The 2024Q2 quarter stands alone, delivering $52.5M of operating income and $0.87 diluted EPS on $80.0M of revenue versus operating losses near $20M in every other period shown, a swing that appears to define the entire ten-quarter history as reported in Fulcrum's filings.

The 78.4% gross margin and 65.6% operating margin in that quarter imply licensing-like economics rather than product economics, and the fact that net income of $55.4M exceeded operating income suggests the period also carried meaningful non-operating gains. Every subsequent comparison is anchored to this anomaly, so normalized profitability should be assessed against the recurring $19M to $27M quarterly operating losses rather than the headline margins.

Non-Operating Swings Cloud Net Losses

Stock-based compensation of $2.5M to $4.3M per quarter represents a persistent drag on reported losses, while net income of $55.4M in 2024Q2 exceeded operating income of $52.5M and 2026Q2's $26.2M loss exceeded its $19.9M operating loss, according to Fulcrum's reported figures.

The gap between operating and net results flips direction across periods, which suggests material non-operating items such as investment marks, interest income or one-off charges are moving through the bottom line and warrant further investigation before the net loss trend is treated as operational. SBC at roughly $2.5M to $4.3M per quarter appears meaningful relative to a recurring net loss of approximately $17M to $26M, so cash-burn economics may differ from reported EPS erosion.

Windfall Recurrence Anchors the Bear Case

Operating expenses have held near $20M per quarter while revenue was absent in nine of ten periods, suggesting the 2024Q2 windfall may prove non-recurring and that the loss trajectory, not the 65.6% peak operating margin, is the operative trend.

A short-seller would likely focus on gross profit being negative in seven of the ten quarters, including -$14.3M in 2025Q3 and -$13.4M in 2025Q1, which implies cost of goods continues to be recognized without corresponding revenue and compresses any path to self-funded operations. The strongest counter-narrative is that peers such as Arrowhead and Amicus post 200%+ and 20% growth on real revenue bases, whereas FULC's implied fundamentals rest on a single quarter, leaving the equity exposed if no follow-on transaction materializes.

Losses Resist Scaling as Spend Falls

Despite R&D declining from $19.3M in 2024Q1 to $12.4M in 2026Q2, the operating loss only narrowed to $19.9M from $29.8M, meaning roughly 70 percent of the research savings were absorbed elsewhere in the cost base.

SG&A rose from $7.7M in 2024Q4 to $8.1M in 2026Q1 while gross profit remained negative, so the expected operating leverage from a leaner pipeline has not fully transmitted to the operating line. Investors should monitor whether the 2026Q1-to-2026Q2 improvement in operating loss, from $22.2M to $19.9M, marks the start of a durable trend or merely quarterly expense phasing.

FULC — Frequently Asked Questions

Quick answers to the most common questions about buying FULC stock.

What was Fulcrum Therapeutics, Inc.'s (FULC) revenue in 2025?

For fiscal year 2025, Fulcrum Therapeutics, Inc. (FULC) reported total revenue of $0.0M.

Is Fulcrum Therapeutics, Inc. (FULC) profitable?

Fulcrum Therapeutics, Inc. (FULC) reported a net loss of $74.9M for the fiscal year ending 2025.